Last reviewed · How we verify
intermittent pivotal βL-AB
Intermittent pivotal βL-AB works by inhibiting the beta-lactamase enzyme.
Intermittent pivotal βL-AB works by inhibiting the beta-lactamase enzyme. Used for Treatment of bacterial infections caused by beta-lactamase-producing bacteria.
At a glance
| Generic name | intermittent pivotal βL-AB |
|---|---|
| Also known as | IID control group |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | β-lactamase inhibitor |
| Target | β-lactamase |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | FDA-approved |
Mechanism of action
This inhibition prevents the degradation of beta-lactam antibiotics, allowing them to be effective against bacterial infections. By preserving the activity of these antibiotics, intermittent pivotal βL-AB helps to combat bacterial infections that would otherwise be resistant to treatment.
Approved indications
- Treatment of bacterial infections caused by beta-lactamase-producing bacteria
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intermittent pivotal βL-AB CI brief — competitive landscape report
- intermittent pivotal βL-AB updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI